IceCure Medical (ICCM) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ICCM Stock Alerts $1.17 0.00 (0.00%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIceCure Medical (NASDAQ:ICCM) Shares Down 3.3% americanbankingnews.com - May 9 at 4:14 AMIndependent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globallyprnewswire.com - May 7 at 8:30 AMHofseth Biocare ASA: HBC ANNUAL REPORT 2023finance.yahoo.com - April 19 at 1:10 PMIceCure Medical (NASDAQ:ICCM) Given "Buy" Rating at HC Wainwrightmarketbeat.com - April 16 at 11:22 AMIceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancerfinance.yahoo.com - April 15 at 12:51 PMIcecure Medical: Strong Buy on Impressive Q4 Revenue and Promising Regulatory Milestonesmarkets.businessinsider.com - April 6 at 9:58 AMIceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call Transcriptseekingalpha.com - April 5 at 2:58 PMIceCure seeks FDA clearance for new cryoablation systemuk.investing.com - April 4 at 1:56 PMIceCure Medical (NASDAQ:ICCM) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSmarketbeat.com - April 4 at 11:57 AMIceCure Medical (NASDAQ:ICCM) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 4 at 8:30 AMIceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearanceprnewswire.com - April 3 at 8:30 AMIceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobesprnewswire.com - April 2 at 8:30 AMIceCure Medical (ICCM) Scheduled to Post Quarterly Earnings on Wednesdaymarketbeat.com - March 28 at 8:31 AMIceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024prnewswire.com - March 27 at 8:30 AMIceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.90 at Alliance Global Partnersmarketbeat.com - March 20 at 12:32 PMHC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM)marketbeat.com - March 20 at 8:11 AMIceCure Medical: ICE3 Cryoablation Breast Cancer Study Shows Positive Resultsmarkets.businessinsider.com - March 19 at 10:51 AMIceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomyfinance.yahoo.com - March 19 at 10:51 AMIceCure Medical Ltd (NASDAQ:ICCM) Short Interest Updatemarketbeat.com - March 13 at 3:59 PMIceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomesprnewswire.com - March 12 at 8:30 AMIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conferenceprnewswire.com - March 7 at 8:30 AMIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conferenceprnewswire.com - March 7 at 8:30 AMIceCure Medical: Strong Buy on Promising Clinical Results and Positive FDA Developmentsmarkets.businessinsider.com - March 5 at 1:25 PMIceCure Medical (NASDAQ:ICCM) Given Buy Rating at HC Wainwrightmarketbeat.com - March 5 at 8:18 AMIceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024prnewswire.com - March 4 at 8:30 AMIceCure Medical Ltd (NASDAQ:ICCM) Sees Significant Increase in Short Interestmarketbeat.com - March 3 at 11:53 PMFourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshopprnewswire.com - February 27 at 8:00 AMStudy Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancerprnewswire.com - February 26 at 8:00 AMIceCure Medical (ICCM) Price Target Increased by 5.85% to 3.14msn.com - February 24 at 2:57 PMIceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japanfinance.yahoo.com - February 15 at 12:52 PMIceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japanprnewswire.com - February 15 at 8:00 AMIceCure Medical Ltd (NASDAQ:ICCM) Expected to Earn FY2023 Earnings of ($0.28) Per Sharemarketbeat.com - February 2 at 7:40 AMBrookline Capital Management Analysts Cut Earnings Estimates for IceCure Medical Ltd (NASDAQ:ICCM)marketbeat.com - February 1 at 7:10 AMFDA agrees to review IceCure request for De Novo classificationmsn.com - January 30 at 7:17 PMU.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancerfinance.yahoo.com - January 30 at 8:43 AMIceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Classfinance.yahoo.com - January 29 at 9:50 AMIceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablationfinance.yahoo.com - January 16 at 10:31 AMIceCure Medical Ltd.: IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rulefinanznachrichten.de - January 13 at 8:46 AMIceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Resultsfinance.yahoo.com - January 10 at 9:40 AMIceCure Medical Publishes Mouse Study On ProSense That Boosts Immune Response Against Cancermarkets.businessinsider.com - January 3 at 12:46 PMNew Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Responsefinance.yahoo.com - January 3 at 12:46 PMStudy Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"finance.yahoo.com - December 13 at 9:36 AMIceCure's ProSense® Deepens Regulatory Approval in Indiafinance.yahoo.com - November 29 at 9:28 AMIceCure shares rally 53% on ProSense kidney cancer studymsn.com - November 28 at 6:12 PM5 Investors Betting Big on IceCure Medical (ICCM) Stockinvestorplace.com - November 28 at 4:13 PMWhat's Going On With IceCure Medical Ltd Stock?msn.com - November 28 at 1:12 PMIceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Ratefinance.yahoo.com - November 28 at 8:11 AMOptimistic Outlook for IceCure Medical’s Stock Despite Revenue Setbacks: Vendetti’s Buy Rating Analysismarkets.businessinsider.com - November 18 at 12:38 AMIceCure stock climbs 10% amid FDA appeal, earnings reportmsn.com - November 15 at 2:41 PMIceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimatesfinance.yahoo.com - November 15 at 2:41 PM Get IceCure Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career… Click For My #1 FREE Crypto for 2024 ICCM Media Mentions By Week ICCM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ICCM News Sentiment▼0.530.41▲Average Medical News Sentiment ICCM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ICCM Articles This Week▼21▲ICCM Articles Average Week Get IceCure Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: APYX News HSAQ News AMIX News SEPA News SRTS News NSPR News CTSO News PDEX News LUCD News MGRM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ICCM) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersUrgent Nvidia WarningAltimetryObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IceCure Medical Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
